Another such compound, zinc [67], is currently in a phase 1 pilot clinical trial because it was found to increase claudin-7 expression in Barrett’s esophagus and prevent the development of esophageal adenocarcinoma. Here, CLDN7 is linked to esophageal adenocarcinoma.